This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Shift to Everolimus (RAD) Kidney Sparing Study

This study has been terminated.
(A cluster of adverse events in everolimus arm was noted.)
Information provided by:
University of Bologna Identifier:
First received: January 9, 2007
Last updated: January 11, 2010
Last verified: May 2009
The purpose of this study is to verify if the combination of Everolimus with a very low dose of cyclosporine is more effective than the combination of mycophenolate mofetil with low-dose of cyclosporine in reducing the progression of kidney dysfunction in patients with heart transplantation.

Condition Intervention Phase
Kidney Dysfunction Heart Transplantation Drug: cyclosporine Drug: Mycophenolate mofetil Drug: Everolimus Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Safety and Efficacy of Low-dose Cyclosporine in Association With Everolimus to Minimize Renal Dysfunction in Heart Transplant Recipients

Resource links provided by NLM:

Further study details as provided by University of Bologna:

Primary Outcome Measures:
  • Calculated GFR [ Time Frame: One year after randomization ]

Enrollment: 34
Study Start Date: September 2006
Study Completion Date: March 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: mycophenolate
Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
Drug: cyclosporine
cyclosporine trough levels between 100 and 150
Drug: Mycophenolate mofetil
mycophenolate with low doses
Active Comparator: Everolimus
Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
Drug: cyclosporine
cyclosporine trough levels between 40 and 90 ng/ml
Drug: Everolimus


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Heart Transplant with 1 to 4 years of follow-up
  • GFR between 20 and 60 ml/min (calculated with Colkoroft-Gault formula)

Exclusion Criteria:

  • Acute rejection in the previous 6 months
  • Contraindications to statin therapy
  • Ongoing infection
  • Ongoing heart failure
  • Myocardial infarction or myocardial revascularization after transplant
  • Malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00420537

Policlinico S.Orsola-Malpighi
Bologna, Italy, 40138
Sponsors and Collaborators
University of Bologna
Study Chair: Angelo Branzi, MD Alma Mater Studiorum University of Bologna
  More Information

Responsible Party: University of Bologna Identifier: NCT00420537     History of Changes
Other Study ID Numbers: 2006-003035-78
Study First Received: January 9, 2007
Last Updated: January 11, 2010

Keywords provided by University of Bologna:
Heart Transplantation
Glomerular Filtration Rate

Additional relevant MeSH terms:
Mycophenolic Acid
Mycophenolate mofetil
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on August 16, 2017